Conclusions : Isoflavone treatments exert a moderately beneficial effect against  estrogen-deficient bone loss in women .
The effect appears dependent on whether isoflavone treatments are in aglycone form ; we conclude that beneficial effects against bone loss may be enhanced for isoflavone aglycones
Background : Age-related estrogen deficiency leads to accelerated bone resorption .
There is evidence that , through selective estrogen receptor modulation , isoflavones may exert beneficial effects against  estrogen-deficient bone loss .
Isoflavone aglycones show higher bioavailability than their glycosidic counterparts and thus may have greater potency .
Objective : To summarize evidence , we executed a systematic review and meta- analysis examining isoflavone therapies and bone mineral density ( BMD ) loss in peri- and postmenopausal women .
Soy isoflavones attenuate bone loss in early postmenopausal Chinese women
Background Previous studies show that daily doses of 40–99 mg soy isoflavones produce inconsistent effects on preventing estrogen-related bone loss in postmenopausal women . Aim of the study To examined the bone-sparing effect of isoflavones at a higher dose in early Chinese postmenopausal women . Methods A total of 90 eligible women aged 45–60 years were r and omly assigned to three treatment groups ( 30 subjects/group ) with daily dosages of 0 ( placebo ) , 84 and 126 mg isoflavones for 6 months . Further inclusion criteria included body mass index < 30 kg/m2 and Kuppermann Climacteric Scale > 15 . Bone mineral density ( BMD ) of the spine and hip were measured using dual- energy X-ray absorptiometry at 0 and 6 months . Serum osteocalcin , bone-specific alkaline phosphatase ( BAP ) and urinary deoxypyridinoline were examined at 0 , 3 and 6 months . Results Mean percent changes in BMD at the lumbar spine ( p = 0.114 ) and femoral neck ( p = 0.053 ) increased with the supplementations of soy isoflavones after adjusting for age , years since menopause , body weight and height , dietary intakes of isoflavones , calcium and protein , physical activities and baseline BMD at the relevant sites . We observed significantly dose-dependent linear relationship between the  supplemental isoflavones  and percent changes of BMD at the spine ( p = 0.042 ) and femoral neck ( p = 0.016 ) post-treatment , and urinary total deoxypyridinoline ( p = 0.014 ) at 12 weeks but not at 24 weeks after adjusting for the above factors . No significant difference in percent changes in serum osteocalcin ( p > 0.05 ) and BAP ( p > 0.05 ) was found among the three treatment groups at 12-week and 24-week post-treatment . Conclusion There is a significantly dose-dependent effect of soy isoflavones on attenuating bone loss at the spine and femoral neck possibly via the inhibition of bone resorption in non-obese postmenopausal Chinese women with high Kuppermann Scale
Conclusions : Isoflavone treatments exert a moderately beneficial effect against  estrogen-deficient bone loss in women .
The effect appears dependent on whether isoflavone treatments are in aglycone form ; we conclude that beneficial effects against bone loss may be enhanced for isoflavone aglycones
Background : Age-related estrogen deficiency leads to accelerated bone resorption .
There is evidence that , through selective estrogen receptor modulation , isoflavones may exert beneficial effects against  estrogen-deficient bone loss .
Isoflavone aglycones show higher bioavailability than their glycosidic counterparts and thus may have greater potency .
Objective : To summarize evidence , we executed a systematic review and meta- analysis examining isoflavone therapies and bone mineral density ( BMD ) loss in peri- and postmenopausal women .